WallStSmart

Basel Medical Group Ltd Ordinary Shares (BMGL)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 572437% more annual revenue ($65.01B vs $11.35M). MRK leads profitability with a 28.1% profit margin vs -93.7%. MRK earns a higher WallStSmart Score of 59/100 (C).

BMGL

Avoid

31

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 4.0
Piotroski: 3/9Altman Z: -1.69

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BMGLUndervalued (+76.8%)

Margin of Safety

+76.8%

Fair Value

$2.59

Current Price

$0.58

$2.01 discount

UndervaluedFair: $2.59Overvalued
MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BMGL2 strengths · Avg: 8.0/10
Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
27.3%8/10

Revenue surging 27.3% year-over-year

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

BMGL4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$11.65M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-163.6%2/10

ROE of -163.6% — below average capital efficiency

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : BMGL

The strongest argument for BMGL centers on Price/Book, Revenue Growth. Revenue growth of 27.3% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bear Case : BMGL

The primary concerns for BMGL are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

BMGL profiles as a growth stock while MRK is a value play — different risk/reward profiles.

BMGL is growing revenue faster at 27.3% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (59/100 vs 31/100), backed by strong 28.1% margins. BMGL offers better value entry with a 76.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Basel Medical Group Ltd Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Basel Medical Group Ltd provides healthcare services. The company is headquartered in Singapore.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?